3+3 Design [Design Issues]

posted by Pharma_88 – China, 2020-01-07 08:09  – Posting: # 21062
Views: 417

Hello All,

This is regarding 3+3 design for Phase-I trial. I have searched online and found some articles on design. My Question is that once the group/cohort is completed with 3 patients, whether same patients will be enrolled in next cohort or new patient will be enrolled? Further, in next cohort suppose 1 patient is withdarwn or have some AE then its compulsory to add 3 more patients to inline with multiplication of 3?

Thanks,
Pharma_88

Complete thread:

Activity
 Admin contact
20,250 posts in 4,262 threads, 1,398 registered users;
online 19 (0 registered, 19 guests [including 13 identified bots]).
Forum time (Europe/Vienna): 06:59 CET

No written law has ever been more binding than
unwritten custom supported by popular opinion.    Carrie Chapman Catt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5